Guosong Liu, MD, PhD – Chief Executive Officer / Founder
Dr. Liu received his PhD in Physiological Sciences from the University of California, Los Angeles in 1990. He completed post-doctoral scientific training at Stanford University and then went on to a faculty position at Picower Institute of Learning and Memory at Massachusetts Institute of Technology, where he remained until 2005. Liu continued a vigorous scientific research program at Tsinghua University. He currently leads and oversees the multiple clinical development programs of Neurocentria.
Dr. Liu is a world renowned expert in synaptic physiology, learning, memory, and emotional control. His research focuses primarily the principles of synaptic density regulation in the brain under physiological and pathological conditions. His discoveries underlie novel strategies for designing molecular targets that treat neurodegeneration and prevent brain atrophy.
Fei Mao, PhD – Chief Chemist / Founder
Dr. Mao, received his PhD in Chemistry from the University of Oregon in 1990. Dr. Mao is a prolific inventor with more than 100 U.S. patents and more than 100 pending U.S. patents. He is also the founder of Biotium, Inc., a world leader in fluorescent molecular reagents – essential tools for biomedical research. Dr. Mao’s fluorescent dyes and probes are widely used for life science research, medical diagnostics, and drug screening, and in particular are useful for determining synaptic density and function. Among his most important inventions is FM1-43, a fluorescent probe co-developed with Professor William J. Betz of the University of Colorado for tracking synaptic transmission in living neurons. FM1-43 was a critical imaging tool used in Dr. Liu’s lab for discovering how synaptic function is regulated, establishing the foundation for Neurocentria’s candidate drug, MMFS.